The Changing Medtech Landscape: The Rise of Reimbursement, An Interview with Mark Leahey

article image
ARTICLE SUMMARY:

In the first of a two-part article, MDMA’s Mark Leahey discusses the progress being made with industry’s relationships with FDA and CMS, and how reimbursement has replaced regulatory as the biggest challenge facing medtech companies.

As he enters his eighteenth year as president and CEO of the Medical Device Manufacturers Association (MDMA), the Washington, DC-based trade group that focuses on small and mid-sized medtech companies, Mark Leahey is the first to acknowledge that he has seen major shifts in many elements of the industry/government landscape.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: